Nuvectis Pharma, Inc. (NVCT) Financials
NVCT Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| March 31, 2026 | 25.4 million | 11.2 million |
| Dec. 31, 2025 | 31.7 million | 13.3 million |
| Sept. 30, 2025 | 35.6 million | 11.6 million |
| June 30, 2025 | 27.0 million | 10.1 million |
NVCT Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| March 31, 2026 | -6.5 million | -460000 |
| Dec. 31, 2025 | -4.0 million | 1.5 million |
| Sept. 30, 2025 | -4.5 million | 1.5 million |
| June 30, 2025 | -3.4 million | 1.7 million |
NVCT Net Income
No data available :(
NVCT Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| March 31, 2026 | 25.1 million | - | - |
| Dec. 31, 2025 | 31.6 million | - | - |
| Sept. 30, 2025 | 35.4 million | - | - |
| June 30, 2025 | 26.8 million | - | - |
NVCT Shares Outstanding
NVCT Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| March 31, 2026 | - | 4.1 million | 2.2 million | - |
| Dec. 31, 2025 | - | 5.1 million | 2.5 million | - |
| Sept. 30, 2025 | - | 5.8 million | 2.0 million | - |
| June 30, 2025 | - | 3.6 million | 3.0 million | - |
NVCT Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| March 31, 2026 | - | - |
| Dec. 31, 2025 | - | - |
| Sept. 30, 2025 | - | - |
| June 30, 2025 | - | - |
NVCT
Price: $11.94
52 week price:
Earnings Per Share: -1.31 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Market Capitalization: 251.2 million